Gliflozins in the Management of Cardiovascular Disease
Eugene Braunwald
Abstract
Gliflozins — sodium–glucose cotransporter 2 inhibitors — lower blood glucose and glycated hemoglobin in patients with type 2 diabetes without causing hypoglycemia. The agents also improve cardiac function in patients who have heart failure with or without type 2 diabetes and improve renal function, with few adverse effects.
Topics & Concepts
MedicineGlycated hemoglobinHypoglycemiaType 2 diabetesDiabetes mellitusRenal functionAdverse effectHeart failureCardiac function curveInternal medicineDiseaseHemoglobinCardiologyIntensive care medicineEndocrinologyDiabetes Treatment and ManagementDiabetes Management and ResearchPancreatic function and diabetes